65,437 trials
Cytomegalovirus Infections
Primary: Number of Participants With Local and Systemic Adverse Events During Seven-Day Follow-Up Period — 11; 14; 13; 5 Participants
Breast Cancer · Hot Flashes · Vaginal Dryness
Primary: Hot Flash Frequency — 2.2; 1.4 daily hot flashes
Pediatric HIV · HIV Infections
Primary: Non-fasting Cholesterol — 187.2; 178.5; 181.5 mg/dL — p=.006
Motivational Intervention · Nicotine Anonymous · Cognitive Behavior Therapy
Primary: Cigarette Use, Average # of Cigarettes Per Smoking Day. — 8.01; 8.87; 8.89; 7.55 days
Obstructive Sleep Apnea
Primary: Mean Apnoea-Hypopnoea-Index (AHI) — 6.21; 7.45 events/hour — p=0.537
Vascular Inflammation · Atherosclerotic Cardiovascular Disease
Primary: Change in Arterial Inflammation — 0.03; 0.20 percent change
Multiple Sclerosis · Exercise Therapy · Dietary Supplement
Primary: VO2max — 40.4; 41.2; 44; 43.4 ml/kg/min
Insulin Resistance, Diabetes
Primary: Percentage Change in Area Under The Curve (AUC) for Blood Glucose 0-2 Hours — 301.09; 258.66; 248.63; 274.13 mmol x min/L — p=0.1146
Neurodegenerative Disease · Weight Loss · Amyotrophic Lateral Sclerosis
Primary: Estimated Mean Change in Weight From Baseline to 6 Months — -0.1; -0.2; -1.2 kg
Hypercholesterolemia · Atherosclerotic Cardiovascular Diseases
Primary: Percentage of Participants With Treatment-emergent Adverse Events (TEAEs) — 78.7; 78.5; 14.0; 14.5 percentage of participants
Recurrent Classic Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma
Primary: Overall Response After 3 Cycles of Botezomib Plus ICE (BICE) Versus Ifosfamide, Carboplatin, Etoposide (ICE) in Patients With Relapsed/Refractory Classical Hodgkin…
Breast Cancer · Hot Flashes · Sexual Dysfunction
Primary: Number of Participants With a 50% Decrease in Hot Flash Score — 50; 53 Participants
Healthy
Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration — 0; 0; 0; 0 Participants
Sickle Cell Disease
Primary: Number of Participants With Sufficient Collection of Hemopoietic Stem Cells (HSCs) Without Serious Adverse Events — 14 Participants
Duchenne Muscular Dystrophy
Primary: Mean Change From Baseline to 24 Weeks in the 6-minute Walk Distance (6MWD) — -3.5; -7.5; -17.0 meter